This bill establishes minimum annual funding levels for Medicaid Disproportionate Share Hospital (DSH) payments to states, directly affecting rural hospitals and state Medicaid programs. For fiscal years 2025 through 2029, it sets a minimum $20 million DSH allotment per state, and for 2030 onward, it requires states to maintain the prior year's minimum amount adjusted for inflation. The provision prevents states from reducing DSH funding below these specified floors, ensuring consistent support for hospitals serving high numbers of low-income patients. It applies to all states receiving Medicaid DSH payments under federal law.
This bill would allow states to waive certain Affordable Care Act requirements for health insurance starting in 2026, provided they maintain a high-risk insurance pool. Residents in participating states would receive funds directly into "Trump Health Freedom Accounts" instead of traditional premium tax credits, which could be used to purchase health insurance with restrictions on coverage for gender transition procedures and abortion services. The bill also modifies tax credits for small employers in participating states and requires better price transparency and outcomes reporting from healthcare providers. It would directly affect residents and small businesses in states that choose to participate in the waiver program.
This bill amends existing law to expand access to mental health services for students in career-focused education programs. It updates the definition of "covered institution" to include both area career and technical education schools (under the Perkins Act) and traditional colleges, ensuring these schools qualify for the same federal mental health and substance use disorder services already available to other higher education institutions. The change directly affects CTE students by making their schools eligible for existing federal funding and support mechanisms. The bill makes no new funding commitments but adjusts legal language to include CTE programs in current service provisions.
This bill makes permanent Medicare telehealth services that allow patients to receive care from home, removing temporary pandemic-era restrictions. It eliminates geographic limitations and expands where telehealth can originate, so beneficiaries in rural or remote areas can consistently access virtual care without needing to travel. The key change modifies Medicare rules to remove expiration dates tied to public health emergencies, ensuring home-based telehealth remains covered indefinitely. This directly affects Medicare beneficiaries, particularly seniors and people with mobility challenges in underserved communities. The policy change simplifies access to routine care without requiring in-person visits.
HRES 1058 is a non-binding House resolution recognizing the federal government’s duty to develop a Transgender Bill of Rights. It calls for specific policy changes, including amending civil rights laws to explicitly prohibit discrimination based on gender identity in employment, housing, and public accommodations; protecting access to gender-affirming medical care; and streamlining legal recognition of gender identity on federal documents like passports and voter registration. The resolution also proposes expanding protections for transgender and nonbinary individuals in healthcare, education, immigration, and correctional facilities, while emphasizing community-led policy development. As a resolution, it does not create new law but sets a framework for future legislative action.
This symbolic resolution (HRES 172) calls for increased awareness and support for chordoma, a rare bone cancer affecting the skull and spine that impacts over 25,000 people globally and about 300 in the U.S. annually. It urges greater funding for accurate diagnosis, new treatments, faster research-to-treatment pathways, and patient-focused drug development. The resolution does not allocate funds or create new laws but formally expresses the House’s support for addressing chordoma’s challenges. It directly affects chordoma patients, families, and researchers seeking improved care options.
This bill would add wigs (classified as cranial prostheses) to Medicare's coverage of durable medical equipment. It requires a dermatologist, oncologist, or treating physician to certify in writing that a wig is medically necessary due to hair loss caused by conditions like cancer, chemotherapy, or autoimmune diseases. Beneficiaries would need this certification to receive coverage for wigs under Medicare Part B. The change directly affects Medicare beneficiaries experiencing hair loss from these specific medical conditions.
This bill extends a Medicaid payment floor ensuring primary care services (like check-ups and vaccinations) are paid at no less than 100% of Medicare rates for children. It directly affects Medicaid-eligible children by expanding access to care from a broader range of providers, including pediatricians, family doctors, nurse practitioners, certified nurse-midwives, and rural health clinics. Key provisions require managed care plans to meet these payment standards and mandate a study tracking enrollment changes, provider participation, and payment rates across states. The study will compare Medicaid payment rates to Medicare benchmarks and analyze state-level variations over time.
This bill removes the requirement for an initial in-person visit before Medicare beneficiaries can receive mental health services via telehealth. It eliminates geographic restrictions that previously limited telehealth access, allowing services to be provided from home or other locations without travel. The change applies immediately to mental health care and substance use disorder treatment, and permanently removes a 2025 deadline that would have ended expanded telehealth access for rural clinics and health centers. This directly affects Medicare patients seeking mental health support, particularly those in rural areas or with mobility challenges.
This bill modernizes how the FDA inspects facilities manufacturing biosimilar drugs (similar but not identical versions of biologic medicines) in the U.S. It requires the FDA to hold a public meeting and issue a report on expanding international inspection agreements, update inspection tools to increase remote assessments (like virtual site reviews), and develop a strategic plan within a year to address staffing and communication challenges specific to biosimilar facility inspections. The bill directly affects FDA inspectors, biosimilar drug manufacturers, and the FDA's inspection processes for domestic facilities. It focuses on improving inspection efficiency and communication without changing drug approval standards or safety requirements.